Contrave: FDA Decision, Chances for Approval

Contrave is a treatment for obesity that consists of bupropion combined with naltrexone. An FDA advisory panel voted 13-7 for its approval in December.  In the end of January, it is going for an official FDA decision. Based on a variety of factors, we would hedge...